164 related articles for article (PubMed ID: 38429536)
21. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
22. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H
Front Immunol; 2024; 15():1389227. PubMed ID: 38803489
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.
Tian L; Li C; Sun J; Zhai Y; Wang J; Liu S; Jiang Y; Wu W; Xing D; Lv Y; Guo J; Xu H; Sun H; Li Y; Li L; Zhao Z
Front Immunol; 2022; 13():1041177. PubMed ID: 36733398
[TBL] [Abstract][Full Text] [Related]
24. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.
Freytes CO; Loberiza FR; Rizzo JD; Bashey A; Bredeson CN; Cairo MS; Gale RP; Horowitz MM; Klumpp TR; Martino R; McCarthy PL; Molina A; Pavlovsky S; Pecora AL; Serna DS; Tsai T; Zhang MJ; Vose JM; Lazarus HM; van Besien K;
Blood; 2004 Dec; 104(12):3797-803. PubMed ID: 15280203
[TBL] [Abstract][Full Text] [Related]
25. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
26. Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation.
Molina JC; Steinberg SM; Yates B; Lee DW; Little L; Mackall CL; Shalabi H; Shah NN
Transplant Cell Ther; 2022 Jan; 28(1):31.e1-31.e9. PubMed ID: 34687939
[TBL] [Abstract][Full Text] [Related]
27. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.
Shadman M; Gauthier J; Hay KA; Voutsinas JM; Milano F; Li A; Hirayama AV; Sorror ML; Cherian S; Chen X; Cassaday RD; Till BG; Gopal AK; Sandmaier BM; Maloney DG; Turtle CJ
Blood Adv; 2019 Oct; 3(20):3062-3069. PubMed ID: 31648329
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy.
Xu Q; Shi Y; Xue L; An F; Xu H; Liu X; Zhu X; Sun Z; Zhai Z; Wang X
Cell Transplant; 2023; 32():9636897231204724. PubMed ID: 37846503
[TBL] [Abstract][Full Text] [Related]
29. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.
Luo L; Jiao Y; Li Y; Yang P; Gao J; Huang S; Huang W; Wang J; Dong F; Ke X; Zou D; Gao C; Jing H
Ann Hematol; 2024 Jun; 103(6):2073-2087. PubMed ID: 38581546
[TBL] [Abstract][Full Text] [Related]
31. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
Maloney DG
Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
Kato K; Sugio T; Ikeda T; Yoshitsugu K; Miyazaki K; Suzumiya J; Yamamoto G; Kim SW; Ikegame K; Uehara Y; Mori Y; Ishikawa J; Hiramoto N; Eto T; Nakazawa H; Kobayashi H; Serizawa K; Onizuka M; Fukuda T; Atsuta Y; Suzuki R
Bone Marrow Transplant; 2024 Mar; 59(3):306-314. PubMed ID: 38102209
[TBL] [Abstract][Full Text] [Related]
33. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
[TBL] [Abstract][Full Text] [Related]
34. [Clinical outcomes of hematopoietic stem cell transplantation for angioimmunoblastic T-cell lymphoma].
Xu LM; Li NN; Wang Z; Wu XX; Dong YJ; Fu XR; Liu Y; Hu LD; Li XF; Wang YN; Wu YM; Ren HY; Zhang MZ; Wang MH; Li YH; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):573-577. PubMed ID: 32397020
[No Abstract] [Full Text] [Related]
35. [Efficacy and safety of chimeric antigen receptor T-cell therapy followed by allogeneic hematopoietic stem cell transplantation in 21 patients with Ph-like acute lymphoblastic leukemia].
Dai HP; Shen HJ; Li Z; Cui W; Cui QY; Li MY; Chen SF; Zhu MQ; Wu DP; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):35-40. PubMed ID: 38527836
[No Abstract] [Full Text] [Related]
36. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
Hamadani M; Benson DM; Hofmeister CC; Elder P; Blum W; Porcu P; Garzon R; Blum KA; Lin TS; Marcucci G; Devine SM
Biol Blood Marrow Transplant; 2009 May; 15(5):547-53. PubMed ID: 19361746
[TBL] [Abstract][Full Text] [Related]
37. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients.
Naik S; Martinez CA; Omer B; Sasa G; Yassine K; Allen CE; Kamdar K; Orth R; Wu M; Leung K; Gottschalk S; Brenner MK; Heslop HE; Krance RA
Blood Adv; 2019 Sep; 3(18):2689-2695. PubMed ID: 31511228
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis.
Du J; Yu D; Han X; Zhu L; Huang Z
JAMA Netw Open; 2021 May; 4(5):e219807. PubMed ID: 34042995
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of clinical outcomes of allogeneic hematopoietic stem cell transplantation for relapsed/refractory peripheral T-cell lymphoma with chemoresistance].
Wang L; Li NN; Wang Z; Wu XX; Dong YJ; Fu XR; Liu Y; Hu LD; Li XF; Wang YN; Wu YM; Ren HY; Zhang MZ; Wang MH; Li YH; Liu DH; Huang WR
Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(48):3786-3791. PubMed ID: 31874515
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
